Soligenix is a late-stage biopharmaceutical company based in Ewing, NJ, dedicated to developing and commercializing products for the treatment of rare diseases with unmet medical needs. With expertise in orphan and unmet medical need indications, Soligenix focuses on specialized biotherapeutics and public health solutions, including treatments for cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn's disease, and psoriasis. The company also has programs aimed at preventing ricin poisoning and developing thermostable vaccines for global use.
Through its pipeline of specialized biotherapeutics and public health solutions, Soligenix aims to address the challenges faced by patients with rare diseases and infectious diseases. With a commitment to innovation and a focus on rare disease treatment, Soligenix is dedicated to improving the lives of patients in need.
Generated from the website